aTyr Pharma, Inc. (ATYR)

NASDAQ: ATYR · Real-Time Price · USD
3.280
-0.060 (-1.80%)
At close: May 9, 2025, 4:00 PM
3.340
+0.060 (1.83%)
After-hours: May 9, 2025, 7:57 PM EDT
-1.80%
Market Cap 291.46M
Revenue (ttm) n/a
Net Income (ttm) -63.41M
Shares Out 88.86M
EPS (ttm) -0.80
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 927,876
Open 3.350
Previous Close 3.340
Day's Range 3.200 - 3.420
52-Week Range 1.420 - 4.660
Beta 0.79
Analysts Strong Buy
Price Target 18.60 (+467.07%)
Earnings Date May 7, 2025

About ATYR

aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; and in Phase 1b/2a clinical trial to treat other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease rela... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date May 7, 2015
Employees 65
Stock Exchange NASDAQ
Ticker Symbol ATYR
Full Company Profile

Financial Performance

In 2024, aTyr Pharma's revenue was $235,000, a decrease of -33.43% compared to the previous year's $353,000. Losses were -$64.02 million, 27.1% more than in 2023.

Financial numbers in USD Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for ATYR stock is "Strong Buy." The 12-month stock price forecast is $18.6, which is an increase of 467.07% from the latest price.

Price Target
$18.6
(467.07% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

aTyr Pharma Announces First Quarter 2025 Results and Provides Corporate Update

Topline data from Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis on track for the third quarter of 2025. Blinded baseline demographics and disease characteristics from Phase 3 EFZO-FI...

2 days ago - GlobeNewsWire

aTyr Pharma Presents Preclinical Data for NRP2-Targeting Antibody ATYR2810 at the American Association for Cancer Research (AACR) Annual Meeting 2025

SAN DIEGO, April 29, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-cl...

10 days ago - GlobeNewsWire

aTyr Pharma to Participate in April Investor Conferences

SAN DIEGO, April 03, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its pro...

5 weeks ago - GlobeNewsWire

aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, March 27, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or “the Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-cl...

6 weeks ago - GlobeNewsWire

aTyr Pharma Announces the Appointment of Dalia R. Rayes as Head of Commercial, Global Efzofitimod Franchise

SAN DIEGO, March 26, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-cl...

6 weeks ago - GlobeNewsWire

aTyr Pharma: Good Safety Data In Pulmonary Sarcoidosis, Institutions Are Accumulating

aTyr Pharma's pivotal data readouts in 2025 for SSc-ILD (Phase 2) and pulmonary sarcoidosis (Phase 3) could significantly impact its market potential and approval prospects. Efzofitimod shows promise ...

2 months ago - Seeking Alpha

aTyr Pharma, Inc. (ATYR) Q4 2024 Earnings Call Transcript

aTyr Pharma, Inc. (NASDAQ:ATYR) Q4 2024 Earnings Conference Call March 13, 2025 5:00 PM ET Company Participants Ashlee Dunston - Senior Director of Investor Relations and Public Affairs Sanjay Shukla...

2 months ago - Seeking Alpha

aTyr Pharma Announces Fourth Quarter and Full Year 2024 Results and Provides Corporate Update

Topline data from Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis expected in the third quarter of 2025. Fourth positive DSMB review for efzofitimod in Phase 3 EFZO-FIT™ study reinforc...

2 months ago - GlobeNewsWire

aTyr Pharma Announces Publication Demonstrating Efzofitimod's Immunomodulatory Activity in Science Translational Medicine

Peer-reviewed publication validates efzofitimod's unique anti-inflammatory mechanism of action on macrophages through neuropilin-2 (NRP2) receptor. Scientific insights further strengthen the rationale...

2 months ago - GlobeNewsWire

aTyr Pharma Announces Fourth Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis

SAN DIEGO, March 06, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-cl...

2 months ago - GlobeNewsWire

aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2024 Financial Results

SAN DIEGO, March 04, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its pro...

2 months ago - GlobeNewsWire

aTyr Pharma to Present at the Leerink Partners Global Healthcare Conference

SAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its prop...

2 months ago - GlobeNewsWire

aTyr Pharma to Present Three Posters for Efzofitimod at the American Thoracic Society (ATS) 2025 International Conference

Blinded baseline demographics and disease characteristics for ongoing Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis; topline data from the study expected in the third quarter of 2025

3 months ago - GlobeNewsWire

aTyr Pharma Announces the Appointment of Eric Benevich to its Board of Directors

SAN DIEGO, Dec. 12, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-cla...

5 months ago - GlobeNewsWire

aTyr Pharma to Present Preclinical Research Demonstrating Anti-Fibrotic Effects of ATYR0101 in Lung and Kidney Fibrosis at Keystone Symposia on Fibrosis

aTyr Pharma to Present Preclinical Research Demonstrating Anti-Fibrotic Effects of ATYR0101 in Lung and Kidney Fibrosis at Keystone Symposia on Fibrosis

5 months ago - GlobeNewsWire

aTyr Pharma to Present Posters on tRNA Synthetase Candidate ATYR0101 at Keystone Symposia on Fibrosis

SAN DIEGO, Nov. 15, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-cla...

6 months ago - GlobeNewsWire

aTyr Pharma: The Bull Has Finally Come Out

aTyr Pharma has a pivotal year ahead with key readouts for Efzofitimod in pulmonary sarcoidosis and SSC-ILD, potentially opening a huge market. Efzofitimod aims to modulate inflammation without immune...

7 months ago - Seeking Alpha

aTyr Pharma to Present at the LD Micro Main Event XVII in October

San Diego, California--(Newsfile Corp. - October 14, 2024) - aTyr Pharma, Inc. (NASDAQ: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicin...

7 months ago - Newsfile Corp

aTyr Pharma: Two 2025 Data Readouts Could Provide Inflection Point

Topline data from phase 3 EFZO-FIT study, using efzofitimod for the treatment of patients with pulmonary sarcoidosis, expected Q3 of 2025. The 7 major pulmonary sarcoidosis markets are expected to rea...

8 months ago - Seeking Alpha

aTyr Pharma to Participate in September Investor Conferences

SAN DIEGO, Aug. 21, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its prop...

9 months ago - GlobeNewsWire

aTyr Pharma Announces Second Quarter 2024 Results and Provides Corporate Update

Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis enrollment completed with 268 patients; topline data from this 52-week study expected in the third quarter of 2025. Ended the second qua...

9 months ago - GlobeNewsWire

aTyr Pharma Announces Nasdaq Stock Ticker Symbol Change from “LIFE” to “ATYR”

SAN DIEGO, June 03, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-cla...

1 year ago - GlobeNewsWire

aTyr Pharma to Present Poster Describing Efzofitimod's Mechanism of Action at the American Thoracic Society 2024 International Conference

SAN DIEGO, May 15, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (aTyr or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class ...

1 year ago - GlobeNewsWire

aTyr Pharma Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis

Independent data and safety monitoring board (DSMB) recommends continuation of study without any modifications. Findings further support favorable safety profile of efzofitimod.

1 year ago - GlobeNewsWire

aTyr Pharma Announces First Quarter 2024 Results and Provides Corporate Update

Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis expected to complete enrollment in the second quarter of 2024. Ended the first quarter 2024 with $87.7 million in cash, cash equivalents...

1 year ago - GlobeNewsWire